does semaglutide increase risk of blood clots How Improves Pressure and Lipid Profiles: A Game-Changer for Health Wegovy Blood Clots Lawsuit [2026

Food and Drug Administration (FDA) approved the GLP-1 medication semaglutide in 2021 for treating obesity

The CDC estimates that some 40% of all adults in the United States are obese, and the demand for GLP-1 injections has been through the roof since they were introduced

Lancet Diabetes Endocrinol 2020;8:37791.PubMed 31

It activates three hormone receptors involved in metabolic regulation : GLP-1 (glucagon-like peptide-1): reduces appetite and slows gastric emptying GIP (glucose-dependent insulinotropic polypeptide): supports insulin response and metabolic efficiency Glucagon: increases energy expenditure and promotes fat utilization Because of this three-pathway action, retatrutide is often described as a triple-agonist medication

Wearable devices beyond activity trackers in youth with obesity: Summary of options

MFU-V / Ultherapy (if indicated) Micro-focused ultrasound with visualisation for non-surgical lifting and tightening of lax skin, assessed on a case-by-case basis